Short-course radiation with chemo and immunotherapy for high-risk rectal cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests a shorter course of radiation given with chemotherapy and immunotherapy before surgery for rectal cancer that has high-risk features. The goal is to see if this combination can shrink tumors more effectively and improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have rectal cancer that has been confirmed by biopsy and is located within 10 cm of the anal verge.
- Your tumor has certain high-risk features seen on MRI, such as being very advanced (T4), having many lymph nodes involved (N2), or showing signs of spread into nearby tissues or blood vessels.
- You have not had any prior treatment for this cancer, such as surgery, radiation, or chemotherapy.
- You are generally healthy enough to undergo treatment, with a performance status of 0 or 1 (meaning you can carry out daily activities).
- Your blood tests and organ function are within acceptable ranges, and you do not have active infections or autoimmune diseases.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a treatment plan involving radiation, chemotherapy, and an immunotherapy drug (a PD-1 inhibitor) for people with a specific type of high-risk rectal cancer. The goal is to see if this combination helps shrink the tumor before surgery.
This trial tests a new approach for people with locally advanced rectal cancer that has high-risk features. It combines short-course radiation with chemotherapy (CapeOX) and the immunotherapy drug toripalimab, with or without another drug called surufatinib, before surgery. The goal is to see if adding these drugs helps shrink the tumor and improve outcomes.
This trial tests a combination of short-course radiation, chemotherapy, and two types of immunotherapy (HLX07 and Serplulimab) before surgery for advanced rectal cancer. It aims to see if this approach helps shrink tumors and improve outcomes.
This trial tests a new treatment sequence for locally advanced rectal cancer: a short course of radiation followed by a combination of immunotherapy (cadonilimab) and chemotherapy (mFOLFOX6) before surgery. The goal is to shrink the tumor more effectively and potentially improve outcomes.
This trial tests a combination of short-course radiation, an immunotherapy drug (adebrelimab), and chemotherapy (CAPEOX) before surgery to help preserve the rectum in people with MSS/pMMR ultra-low rectal cancer. The goal is to shrink the tumor enough to avoid removing the rectum.
This trial tests a combination of chemotherapy, radiation, and an immunotherapy drug (serplulimab) for people with rectal cancer that has spread to just a few spots in the body (no more than 5 tumors in up to 2 locations). It aims to see if this approach is safe and effective.
Hear when a new Rectal Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.